ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2
ARMAS PHARMACEU
Drug class
Antineoplastic - Protein-Tyrosine Kinase Inhibitors
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies. Read more about Antineoplastic - Protein-Tyrosine Kinase Inhibitors
170 drugs in this class 83 manufacturers
Drugs in Antineoplastic - Protein-Tyrosine Kinase Inhibitors
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ·+11
ARMAS PHARMACEU
ROMVIMZA (vimseltinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · TENOSYNOVIAL GIANT CELL TUMOR
DECIPHERA PHARM
IMKELDI (imatinib mesylate)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ·+11
SHORLA PHARMA I
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ·+11
QUALLENT PHARMA
PAZOPANIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · SOFT OR CONNECTIVE TISSUE SARCOMA ·+1
NOVUGEN PHARMA
SUNITINIB MALATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · RENAL CELL CARCINOMA ·+3
NOVUGEN PHARMA
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2
TEVA USA
SUNITINIB MALATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · RENAL CELL CARCINOMA ·+3
TEVA USA
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Protein-Tyrosine Kinase Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies.
They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis.
Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer.
-
nih.gov
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer
-
nih.gov
Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis
-
nih.gov
They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis
-
rxlist.com
Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.